Deep Medicine, a new book from cardiologist Eric Topol, MD, explores the evolving relationship between artificial intelligence (AI) and healthcare. The New York Times interviewed Topol about the book, and AI’s impact on radiology was one of the first topics that came up.
The American College of Cardiology (ACC) will begin offering a new Transcatheter Valve Certification to U.S. hospitals in mid-2019, the College announced March 13.
Follow-up imaging adherence rates vary based on a number of factors, according to new research published in the American Journal of Roentgenology. The authors noted that closely monitoring such patterns can help providers engage patients and minimize risk.
The FDA fast-tracked the approval process for a new generic valsartan product (Diovan) amid an ongoing shortage of the blood pressure and heart failure medication.
A new noninvasive imaging technique can identify small abnormalities in the airways of patients with chronic obstructive pulmonary disease (COPD), according to research published in the American Journal of Respiratory and Critical Care Medicine.
Norman E. Sharpless, MD, director of the National Cancer Institute (NCI) since October 2017, has been announced as the new acting commissioner of the FDA. Sharpless replaces Scott Gottlieb, MD, who unexpectedly resigned from the position on March 5.
President Trump’s budget proposal for 2020 would negatively impact almost every institute at the NIH, including trimming the funding for the National Heart, Lung and Blood Institute by about $486 million.
A napping habit could lower blood pressure to a similar extent as other lifestyle modifications and some drugs, according to research scheduled to be presented March 18 at the American College of Cardiology’s scientific sessions in New Orleans.
The SPRINT trial suggested a more aggressive blood pressure-lowering target reduced the rate of cardiovascular events in hypertensive people, but a new secondary analysis of the trial indicates such an approach may actually be harmful for smokers.
When it comes to digital medicine, digital pathology is very late to the game. But its time is coming. And the benefits could be many: Bolstering the capabilities, efficiency and reach of individual pathologists, cutting patient wait times, streamlining multidisciplinary team meetings (MDTs) and offering more data-rich decision-making. It could even obviate a shortage of pathologists. Where does it fit into your strategic plan?
